NCT06764771RecruitingPhase 1
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
A Phase 1/1b Open-label Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
Source: ClinicalTrials.gov · Last updated 29 Jul 2026
Brief summary (registry, in English)
This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 437 (estimated)
- First submitted
- 3 Jan 2025
- Start date
- 25 Mar 2025
- Primary completion date
- 15 Oct 2027
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Kidney cancer, Lung cancer, Colorectal cancer
- NCT number
- NCT06764771
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 437
- From 25 Mar 2025 to the primary completion date, 15 Oct 2027
- 8 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of prior severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
- \- Other protocol-defined inclusion/exclusion criteria apply.
Other illness
- Impaired cardiac function or clinically significant cardiac disease.
- For Parts 1B, 1C, 2B, 2C only (combination with adagrasib):.
- History of pneumonitis or interstitial lung disease (ILD).
Other
- Untreated central nervous system (CNS) metastases.
- Leptomeningeal metastasis (carcinomatous meningitis).
Who the study is looking for
- Participant must be ≥ 18 years of age.
- Histologically confirmed diagnosis of a locally advanced and unresectable or metastatic solid tumor malignancy with any of the following tumor types:.
- Part 1A: clear-cell renal cell carcinoma (ccRCC), clear-cell ovarian cancer (ccOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC).
- Parts 2A, 1D, 2D: ccRCC.
- Part 1B: solid tumors with KRAS G12C mutation.
- Part 2B: NSCLC with KRAS G12C mutation.
- Parts 1C, 2C: colorectal cancer (CRC) with KRAS G12C mutation.
- Participants must have an Eastern Cooperative Oncology Groups (ECOG) Performance Status of 0 or 1.
- Participants must have measurable disease per RECIST v1.1.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (8)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Brisbane | Australia | Active, not recruiting |
| - Coordinator of this site? Confirm its status | Montreal | Canada | Not yet recruiting |
| Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus Coordinator of this site? Confirm its status | Québec | Canada | Recruiting |
| BC Cancer - Vancouver Coordinator of this site? Confirm its status | Vancouver | Canada | Recruiting |
| - Coordinator of this site? Confirm its status | Allentown | United States | Active, not recruiting |
| - Coordinator of this site? Confirm its status | Dallas | United States | Withdrawn |
| The West Clinic, PLLC dba West Cancer Center Coordinator of this site? Confirm its status | Germantown | United States | Recruiting |
| John Theurer Cancer Center at Hackensack University Medical Center Coordinator of this site? Confirm its status | Hackensack | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.